ADOLOR SUBMITS ADL5747 IND FOR DELTA OPIOID RECEPTOR TARGET.Adolor Corporation, Exton, Pa., (Nasdaq:ADLR) has announced that clinical testing will be permitted under an Investigational New Drug Application (IND) for ADL5747, a novel oral compound that targets the Delta opioid receptor δ-Opioid receptors are a class of opioid receptor which have enkephalins as their endogenous ligands. Function Activation of the receptors produces analgesia. Some research suggests that they may also be related to seizures. . Adolor expects to initiate Phase 1 clinical testing in the first quarter of 2008. ADL5747 is the second delta compound that will enter clinical investigation under Adolor's worldwide collaboration with Pfizer Inc (NYSE NYSE See: New York Stock Exchange :PFE 1. (text, editor) PFE - Programmer's File Editor. 2. (language) PFE - Portable Forth Environment. ) to develop novel pain compounds. A lead compound, ADL5859, is in Phase 2 clinical testing in several pain conditions. About the Delta Receptor Program The Delta receptor is one of three opioid receptors Opioid receptors Receptors located in the brain and various organs that bind opiates or opioid substances. Mentioned in: Methadone opioid receptors, n.pl any of the several receptors to which opiates bind. . Through a proprietary research platform based on cloned, human opioid receptors, Adolor has identified a series of novel, orally active Delta agonists compounds that selectively stimulate the Delta opioid receptor. Delta compounds may have a number of potential advantages, including an improved side effect profile, as compared to mu opioid receptor The μ opioid receptors (MOR) are a class of opioid receptors with high affinity for enkephalins and beta-endorphin but low affinity for dynorphins. The opiate alkaloids morphine and codeine are known to bind to this receptor. agonists. On the basis of preclinical evaluation in animal models of human conditions, one might expect a Delta agonist to show effect in inflammatory pain, among other pain conditions. In addition, Delta agonists are thought to modulate other biological processes that may manifest themselves in disease states or conditions such as cardioprotection, overactive bladder Overactive Bladder Definition Overactive bladder is the leakage of large amounts of urine at unexpected times, including during sleep. Description , and depression. There are currently no selective Delta agonists approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . About the Delta Collaboration Adolor and Pfizer Inc (NYSE:PFE) are collaborating on the worldwide development and commercialization of two novel Delta opioid agonist compounds, ADL5859 and ADL5747, for the treatment of pain. About Adolor Corporation Adolor Corporation (Nasdaq:ADLR) is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. Adolor has two lead product candidates in development: Entereg[R] (alvimopan) for the management of the gastrointestinal side effects Side effects Effects of a proposed project on other parts of the firm. associated with opioid use; and, novel Delta opioid receptor agonists for a variety of pain indications. Adolor and GlaxoSmithKline are collaborating in the worldwide development and commercialization of Entereg in multiple indications. Adolor and Pfizer are collaborating in the worldwide development and commercialization of two Delta agonists for pain. Adolor also has a number of discovery research programs focused on the identification of novel compounds for the treatment of pain. By applying its knowledge and expertise in pain management, along with ingenuity, Adolor is seeking to make a positive difference for patients, caregivers and the medical community. For more information, visit http://www.adolor.com or call 484/595-1500. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion